Establishment Labs Holdings (ESTA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.23
- Surprise
- —
- Score today
- 5.9/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- Establishment Labs Hldgs Q3 2026 Earnings Call Transcript — benzinga, 2026-10-29
- Establishment Labs Hldgs FY2026 Revenue expected to be more than $274.000M vs $270.215M Est — benzinga, 2026-10-29
- Establishment Labs Hldgs Q3 EPS $(0.35) Misses $(0.26) Estimate, Sales $71.993M Beat $66.460M Estimate — benzinga, 2026-10-29
Where TrendMatrix's rating stands now
TrendMatrix currently rates ESTA Sell at 5.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate.
What argues against it
- Concentration risk — Supplier: single-source silicone supplier
- Quality below floor (3.7 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $64.35
- Price target
- $85.69
- Stop
- $59.85
- Upside to target
- +33.2%
- Reward-to-risk
- 2.3:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
ESTA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $2.06B
- P/E (fwd)
- 1149.5
- 52-week range
- $47.00–$97.59
- Off 52-week high
- 34.1%
- RSI (14)
- 55
- Volume vs avg
- 0.11×
- Score today
- 5.9/10